<qa>  What is the name of the study that is performed at baseline?Patients undergo blood, urine, and tissue sample collection for pharmacogenomic, pharmacokinetic, and biomarker laboratory studies. Blood and urine samples are collected at baseline, after 1 week of treatment, and at the time of surgery for pharmacokinetic and urine biomarker survivin and BLCA-4 studies. Pharmacogenomic studies epidermal growth factor receptor EGFR polymorphisms and CYP3A 45 genotypes are performed at baseline using blood samples. Tissue biomarker EGFR polymorphism, EGFR mutations EGFR vIII, exon 19-21, EGFR, phosphorylated EGFR, Ki67, activated caspase 3, Akt, P-Akt, MAP kinase, P-MAP kinase, COX-2, survivin, and BLCA4 studies using tumor tissue and adjacent and remote normal urothelium are performed at baseline and at the completion of treatment. 